ArticleEuropean journal of heart failure2020
Phenomapping of patients with heart failure with preserved ejection fraction using machine learning-based unsupervised cluster analysis.
Article in European journal of heart failure, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06478277 (The UK CARDIOvascular Immune-Mediated Inflammatory Diseases), which is not on this map. Cited by 160 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The UK CARDIOvascular Immune-Mediated Inflammatory Diseases (CARDIO-IMID) Registry
Who cites it
160 citing papers in PubMed, 6 syntheses or guidelines pooled it, 294 citations in OpenAlex.
- Artificial Intelligence-Based Echocardiographic Assessment of Diastolic Dysfunction: A Systematic Review.Echocardiography (Mount Kisco, N.Y.) · 2026Pooled it
- Machine learning based insights into cardiomyopathy and heart failure research: a bibliometric analysis from 2005 to 2024.Frontiers in medicine · 2025Pooled it
- Discovering Distinct Phenotypical Clusters in Heart Failure Across the Ejection Fraction Spectrum: a Systematic Review.Current heart failure reports · 2023Pooled it
- C-Reactive Protein, Interleukin-6, Trimethylamine-N-Oxide, Syndecan-1, Nitric Oxide, and Tumor Necrosis Factor Receptor-1 in Heart Failure with Preserved Versus Reduced Ejection Fraction: a Meta-Analysis.Current heart failure reports · 2023Pooled it
- Redefining β-blocker response in heart failure patients with sinus rhythm and atrial fibrillation: a machine learning cluster analysis.Lancet (London, England) · 2021Pooled it
- Pooled it
- Phenomapping-derived selection of fractional flow reserve or optical coherence tomography to personalise percutaneous coronary intervention.Open heart · 2025Trial
- Phenomapping the Response of Patients With Ischemic Cardiomyopathy With Reduced Ejection Fraction to Surgical Revascularization.Clinical cardiology · 2025Trial
- Risk stratification of ST-segment elevation myocardial infarction (STEMI) patients using machine learning based on lipid profiles.Lipids in health and disease · 2021Trial
- Heart failure with preserved ejection fraction shows no excess mortality in older patients: a population-matched relative survival analysis.GeroScience · 2026Observational
- Modeling heart failure with preserved ejection fraction (HFpEF) likelihood among women with suspected coronary microvascular dysfunction (CMD).American heart journal plus : cardiology research and practice · 2026Article
- Predicting left-ventricular recovery and characterizing Cardiorenal risk after Transcatheter aortic valve replacement: A routine-data phenotyping and prediction-model study.International journal of cardiology. Heart & vasculature · 2026Article
- The Intersection of Heart Failure with Preserved Ejection Fraction and CKD.Clinical journal of the American Society of Nephrology : CJASN · 2026Review
- Longitudinal phenotyping of heart failure with preserved ejection fraction identifies early- and end-stage disease states.Open heart · 2026Article
- Exploratory Mixed-Data Phenomapping and Risk-Enrichment Frameworks for Long-Term Mortality After Acute Coronary Syndrome: A Single-Center Cohort Study.Medicina (Kaunas, Lithuania) · 2026Article
- Echocardiographic Phenomapping in HFpEF: From Imaging Biomarkers to Precision Cardiovascular Medicine.Echocardiography (Mount Kisco, N.Y.) · 2026Review
- Cardiac energetics and ventriculo-arterial interaction-based phenotyping in heart failure: a machine learning analysis.The international journal of cardiovascular imaging · 2026Article
- Phenotyping of Patients With Clinical Features of Advanced Heart Failure: A Latent Class Analysis of a Multicenter Registry of Patients Hospitalized With Heart Failure.Journal of the American Heart Association · 2026Article
- Absence of GDF15 Aggravates Pressure Overload-Induced Cardiac Remodelling in Mice Hallmarked by Perivascular Fibrosis and Signs of Endothelial-to-Mesenchymal Transition.International journal of molecular sciences · 2026Article
- Artificial Intelligence in Heart Failure with Preserved Ejection Fraction.Diagnostics (Basel, Switzerland) · 2026Review
100 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
aimTo identify distinct phenotypic subgroups in a highly-dimensional, mixed-data cohort of individuals with heart failure (HF) with preserved ejection fraction (HFpEF) using unsupervised clustering analysis. METHODS AND
resultsThe study included all Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) participants from the Americas (n = 1767). In the subset of participants with available echocardiographic data (derivation cohort, n = 654), we characterized three mutually exclusive phenogroups of HFpEF participants using penalized finite mixture model-based clustering analysis on 61 mixed-data phenotypic variables. Phenogroup 1 had higher burden of co-morbidities, natriuretic peptides, and abnormalities in left ventricular structure and function; phenogroup 2 had lower prevalence of cardiovascular and non-cardiac co-morbidities but higher burden of diastolic dysfunction; and phenogroup 3 had lower natriuretic peptide levels, intermediate co-morbidity burden, and the most favourable diastolic function profile. In adjusted Cox models, participants in phenogroup 1 (vs. phenogroup 3) had significantly higher risk for all adverse clinical events including the primary composite endpoint, all-cause mortality, and HF hospitalization. Phenogroup 2 (vs. phenogroup 3) was significantly associated with higher risk of HF hospitalization but a lower risk of atherosclerotic event (myocardial infarction, stroke, or cardiovascular death), and comparable risk of mortality. Similar patterns of association were also observed in the non-echocardiographic TOPCAT cohort (internal validation cohort, n = 1113) and an external cohort of patients with HFpEF [Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Heart Failure with Preserved Ejection Fraction (RELAX) trial cohort, n = 198], with the highest risk of adverse outcome noted in phenogroup 1 participants.
conclusionsMachine learning-based cluster analysis can identify phenogroups of patients with HFpEF with distinct clinical characteristics and long-term outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.